March 29, 2023 4:41pm

It’s an honor to be considered the “canary in the (sectors) coal mine”! 

Is Avrobio (AVRO -$0.08 to $0.97 with 489 K shares traded, 3-month average = 1.345 M shares) headed to be de-listed (below the $1.00 requirement of Nasdaq) – again?

Pre-open Indications: 2 Hits and 2 Miss

Earnings: bluebird bio (BLUE) reports Q4 and FY22 net losses, missing per share and revenue estimates

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!  

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +323.35 points (+1%), the S&P closed UP +56.54 points (+1.42%) while the Nasdaq closed UP +210.16 points (+1.79%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes rose on Wednesday after falling Tuesday, as solid gains in the cell and gene therapy and tech helped the Nasdaq rebound. Sentiment was also lifted by easing concerns around the banking sector.

Economic Data Docket: home sales from the National Association of Realtors showed homes under contract rose for the third-straight month in February.

 

Pre-open Indications: 2 Hits <CRISPR Therapeutics (CRSP +$1.33), Beam Therapeutics (BEAM +$0.86)> and 2 Miss <Ultragenyx (RARE +$1.41), Ionis Pharmaceuticals (IONS +$1.19)>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences

  • Wednesday’s advance/decline line opened positive at 31 up/ 2 down and 2 flats, stayed positive with 31 up/ 4 down and 0 flat at the mid-day, ending with a positive close of 31/4 and 0 flat

 

All time low:

  • bluebird bio (BLUE) at $3.30

 

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … https://www.regmedinvestors.com/articles/12843 - 29 of 35 – added BLUE

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was up +1.40% and the XBI was up +2.50%

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.83 points or -4.16% at 19.14

 

Closing Down (4 of 4):

  • bluebird bio (BLUE -$1.06),
  • Cellectis SA (CLLS -$0.11),
  • Avrobio (AVRO -$0.08),
  • Adverum Biotechnologies (ADVM -$0.045),

Closing Up (10 of 31):

  • Alnylam Pharmaceuticals (ALNY +$7.36 after Tuesday’s -$1.96 and Monday’s +$0.53),
  • Sage Therapeutics (SAGE +$1.96 after Tuesday’s -$1.60 and Monday’s +$0.47),
  • Intellia Therapeutics (NTLA +$1.54 after Tuesday’s -$1.13 and Monday’s -$1.15),
  • Ultragenyx (RARE +$1.41 after Tuesday’s +$0.33 and Monday’s -$0.35),
  • CRISPR Therapeutics (CRSP +$1.33 after Tuesday’s -$0.50 and Monday’s +$0.92),
  • Ionis pharmaceuticals (IONS +$1.19 and Monday’s -$0.23),
  • Beam Therapeutics (BEAM +$0.86 and Tuesday’s -$0.38),
  • Chinook Therapeutics (KDNY +$0.69),
  • Prime Medicine (PRME +$0.64 after Tuesday’s +$0.02 and Monday’s +$0.66),
  • Vericel (VCEL +$0.60 after Tuesday’s -$0.92),

 

Q1/23 – March

  • Wednesday closed positive with 31 incliner, 4 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Sentiment is skittish at the moment and markets will be prone to swings <Kallum Pickering, senior economist at Berenberg>

Amid a somewhat slower calendar for corporate and economic news,

The sector rallied after a down Tuesday which followed three (3) positive closes.

The rush of Q4 and FY22 earnings to release is slowing as … 28 of my 35 covered have reported.

Upcoming Q4 earnings reporting will present challenges to share pricing.

·         bluebird bio (BLUE) reported today,

·         Six (6) more releases forthcoming of my 35 covered companies

·         Brainstorm Cell Therapeutics (BCLI) 3/30 - Thursday

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

Remember, there are four (4) phases of the stock cycle: accumulation; markup; distribution; and markdown.

As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect.”

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

The NO spin zone!

Biostage (OTCQB: BSTG) – still pumping the volume and TRYING to promote the share price!!

Wednesday closed up +$0.16 with 1,200 shares traded afterTuesday closed down -$0.51 with 3,895 shares traded after Monday closed flat with 25 shares traded <3-month average volume = 1,740 shares>

·         Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold??

·         Let’s also welcome a NEW accounting firm – the fourth (4th) in five (5) years. When will they resign …??

·         Where is the SEC??

·         NEW Auditors must consider whether there is substantial doubt about a company’s ability to continue as a going concern, an assessment of the company’s viability over the next year.

·         As OTCQB: BSTG continues as an “going concern”!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.